Clinical trialNCT06993844RecruitingPhase 1/PHASE2Interventional

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

SponsorEnsem TherapeuticsEnrollment233Advanced Breast CancerAdvanced Solid Tumors

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China

Beijing Luhe Hospital,capital Medical University
Beijing, China
Dong Yan, MD
Recruiting
Fujian Cancer Hospital
Fuzhou, China
Fan Wu, MD
Recruiting
Sun Yat-Sen University Cancer Center
Guangzhou, China
Shusen Wang, MD
Recruiting
Shandong Cancer Hospital&institute
Shandong, China
Huihui Li, MD
Recruiting
Fudan University Shanghai Cancer Hospital
Shanghai, China
Hongxia Wang, MD
Recruiting

United States

Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
Monica Mita, MD
Recruiting
Ucsf Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
Varun Monga, MD
Recruiting
Yale University, Yale Cancer Center
New Haven, Connecticut, United States
Adriana Kahn, MD
Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Gerburg Wulf, MD
Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Sarah Simmons, MD
Recruiting
Carolina Biooncology Institute
Huntersville, North Carolina, United States
Neel Gandhi, MD
Recruiting
the University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Jordi Rodon Ahnert, MD, PhD
Recruiting
Start
San Antonio, Texas, United States
Amita Patnaik, MD, FRPC
Recruiting
Next
Fairfax, Virginia, United States
Alex Spira, MD, PhD, FACP
Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington, United States
Jennifer M Specht, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

ETX-636 dose escalationETX-636 dose escalation in combination with fulvestrantETX-636 dose expansion in combination with fulvestrant

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 10 Jun 2025
Primary completion: 30 Jun 2027
Completion: 30 Dec 2027
Last update posted: 23 Jun 2026
Registered enrollment: 233
Registry id: NCT06993844

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.